Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Lexington, Massachusetts and currently employs 169 full-time employees. The company went IPO on 2020-04-08. The firm is focused on developing and commercializing novel therapeutics to treat a range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (TGF-B), family of proteins. Its lead product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, and in patients with myelofibrosis. Its product candidate, KER-012, is being developed for the treatment of pulmonary arterial hypertension, or PAH, and for the treatment of cardiovascular disorders. Its product candidate, KER-065, is being developed for the treatment of obesity and for the treatment of neuromuscular diseases. KER-050 is designed to raise red blood cell and platelet production by inhibiting the signaling of a subset of the TGF-B family of proteins to promote hematopoiesis.
Follow-Up Questions
Who is the CEO of Keros Therapeutics Inc?
Dr. Jasbir Seehra is the Chairman of the Board of Keros Therapeutics Inc, joining the firm since 2015.
What is the price performance of KROS stock?
The current price of KROS is $15.91, it has decreased 0.81% in the last trading day.
What are the primary business themes or industries for Keros Therapeutics Inc?
Keros Therapeutics Inc belongs to Biotechnology industry and the sector is Health Care
What is Keros Therapeutics Inc market cap?
Keros Therapeutics Inc's current market cap is $646.2M
Is Keros Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 10 analysts have made analyst ratings for Keros Therapeutics Inc, including 5 strong buy, 6 buy, 6 hold, 0 sell, and 5 strong sell
